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ISSNObjective: HIV-infected patients with treated cryptococcal meningitis are at risk for
further neurological deterioration after commencing combination antiretroviral therapy
(cART), mostly because of cryptococcosis-associated immune reconstitution inflam-
matory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratifica-
tion.
Design: Prospective, longitudinal cohort study for 24 weeks.
Setting: Durban, South Africa.
Participants: One hundred and thirty HIV-infected patients with first cryptococcal
meningitis episode
Intervention: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by
consolidation and maintenance fluconazole) and cART (commenced median of 18 days
from cryptococcal meningitis diagnosis).
Main outcome measure: Clinical, blood, and cerebrospinal fluid (CSF) markers associ-
ated with C-IRIS before and during cART and clinical significance of CSF cryptococcal
culture negativity pre-cART commencement.
Results: Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%)
neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration.
On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal
growth [hazard ratio (HR) 0.27, P¼0.026] and lower CSF protein (HR 0.53, P¼0.059)
prior to cART and lower CD4þ T-cell increases (HR 0.99, P¼0.026) but not change in
HIV viral load during cART. Using survival analysis, patients with a negative crypto-
coccal culture pre-cART commencement (n¼51; 48.1%) experienced fewer episodes
of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than
patients with culture positivity (n¼55; 51.9%, HR 0.33, 0.33, and 0.12 and
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Propelled by the HIV epidemic, cryptococcal meningitis
is currently the leading cause of adult meningitis in central
and southern Africa. Globally, two-thirds of the 1 million
patients with cryptococcal meningitis are estimated to die
within 3 months of diagnosis [1]. Patients with HIV
infection who survive cryptococcal meningitis to
commence combination antiretroviral therapy (cART)
often experience further neurological deterioration
presenting with worsening headaches, seizures, or
confusion. This can lead to further invasive procedures
and hospital admissions for empirical re-treatment of
cryptococcal meningitis and is associated with significant
morbidity and mortality. A large proportion of these
neurological deterioration events are likely because of
paradoxical cryptococcosis-associated immune reconsti-
tution inflammatory syndrome (C-IRIS).
Paradoxical C-IRIS is a form of immune restoration
disease, a condition resulting from heightened immune
responses against viable and/or nonviable opportunistic
pathogens that cause immunopathology at various sites
[2] and has been reported in up to 50% of patients
following commencement of cART [3]. Diagnosis of
immune restoration disease requires careful exclusion of
alternative diagnoses, a temporal association to cART
commencement, and evidence of a virological response
to cART [4–6]. Specific definitions for diagnosis of
C-IRIS have been published [7], although diagnosis
remains difficult. To date, there are no clear predictive or
diagnostic markers for C-IRIS.
Evidence is accruing against very early commencement of
cART after diagnosis of cryptococcal meningitis in HIV-
infected patients with three randomized studies demon-
strating that deferring cART conferred a survival advantage
[8–10]. Death following early initiation of cART has been
postulated to be linked to C-IRIS. This is in contrast to
evidence from tuberculosis (TB)-HIV coinfection studies
in which early cART initiation increased survival in
patients with advanced immunodeficiency [11,12],
although not in tuberculous meningitis [13].
We sought to define the causes of neurological deteriora-
tion post-cART commencement and to identify thepincott Williams & Wilkins. Unauthoclinical and mycological predictors of C-IRIS. In
particular, we hypothesized that cryptococcal clearance
prior to cART commencement would be associated with
improved clinical outcomes.Methods
Study design and participants
Between August 2009 and March 2011, we consecutively
enrolled 130 cART-naive, HIV-infected patients experi-
encing their first episode of cryptococcal meningitis into
a prospective, longitudinal cohort study in Durban, South
Africa. Patients were 18 years of age or older with a
positive cryptococcal antigen (CrAg) or India ink test on
cerebrospinal fluid (CSF). Written informed consent was
given by the patients or their next-of-kin. Ethics approval
was granted by the Biomedical Research and Ethics
Committee of University of KwaZulu Natal (BF053/09),
Monash University (2009001224), and University of
Western Australia (RA/4/1/2541).
Antifungal therapy and combination antiretroviral
therapy
Patients were jointly managed by the local treating
team and a single study physician who supervised the
management of all patients. Each patient was treated
with induction therapy using intravenous amphotericin
(1 mg/kg) for 14 days and therapeutic lumbar punctures
were performed as clinically indicated, as per local
guidelines [14]. Patients then received 8–12 weeks of
consolidation therapy using fluconazole 400 mg followed
by 200 mg as maintenance therapy, with a 50% dose
increase for patients receiving rifampicin concurrently.
Flucytosine (5-FC) was not available. Standard cARTwas
commenced based on clinical judgment: improvement in
conscious state; no further headaches, neck stiffness, con-
fusion, seizures, or vomiting; and improvement in opening
pressure (wherever possible, aiming for <25 cmH2O),
improvement in renal function, and patient-readiness to
initiate cART.
Just prior to cART commencement a lumbar puncture
was performed (termed ‘clearance lumbar puncture’).
The cART regimen was composed of stavudine/
lamivudine/efavirenz until April 2010 when stavudinerized reproduction of this article is prohibited.
Cryptococcosis-IRIS predictors Chang et al. 2091was replaced with tenofovir in the national guidelines
[15]. Patients were prospectively followed at a minimum
interval of 4 weeks, for 24 weeks from the time of cART
commencement. Patients were also systematically eval-
uated at each clinical visit and data recorded on case
report forms, specifically designed to capture data on
neurological deterioration. Phone and short-messaging
services were utilized to enhance follow-up.
Classification of neurological deterioration
events
Patients were educated thoroughly on the natural history
of cryptococcal meningitis and HIVand were informed of
the possibility of further neurological deterioration and
the need for urgent assessment should this arise. The study
physician was available by phone 24 h a day, 7 days a week
for the duration of the study, and patients and families
were encouraged to contact the physician if necessary.
Symptoms and signs suggestive of neurological deteriora-
tion such as worsening headaches, seizures, confusion,
neck stiffness, visual change, or limb weakness triggered
consideration of a neurological deterioration event. All
events were investigated and managed by the study
physician in association with local treating teams.
Details of each neurological deterioration episode was
retrospectively analyzed by an end-point review com-
mittee consisting of the study physician and three
experienced HIV physicians and classified as probable-
C-IRIS, possible-C-IRIS, neurological deterioration-
not C-IRIS, or indeterminate, based on predefined
criteria [7]. Patients with a clear alternative explanation
for their neurological deterioration or noncompliance to
antifungal therapy with a clear increase in cryptococcal
CSF load consistent with cryptococcal persistence/
relapse were classified as neurological deterioration-not
C-IRIS. Patients with inadequate information (e.g.
sudden death at home) were classified as indeterminate.
Definitions of possible-C-IRIS and probable-C-IRIS
differed only in the strength of the evidence for C-IRIS
and both groups were therefore classified as C-IRIS for
analyses of predictors of C-IRIS. Patients who did not
experience any neurological deterioration were classified
as no neurological deterioration.
Examination of cerebrospinal fluid samples and
classification by clearance lumbar puncture
All CSF samples underwent routine analysis for cell
count, Gram stain, and India ink testing and were
cultured for 30 days. In addition, CSF samples collected at
cryptococcal meningitis diagnosis, at clearance lumbar
puncture and at neurological deterioration underwent
quantitative cryptococcal culture (QnCC). In brief,
100 ml of undiluted CSF was cultured, followed by
10-fold serial dilution on five further plates. Remaining
CSF was centrifuged and sediment plated on a qualitative
plate. CSF and serum CrAg was quantified by latex
agglutination (CALAS; Meridian Bioscience, Cincinnati,Copyright © Lippincott Williams & Wilkins. UnautOhio, USA) to a maximum titer of 1 : 1024. All patients
had a clearance lumbar puncture performed. On the basis
of the clearance lumbar puncture, patients were classified
as ‘culture negative’, if their qualitative cultures were
negative for cryptococcal growth at 30 days, and ‘culture
positive’ if their cultures were positive. This classification
was blinded to the treating clinicians.
Statistical analysis
Categorical variables were summarized using frequency
and percentages and were compared using a chi-square
test or a Fisher’s exact test wherever appropriate.
Continuous variables were assessed for skew and
summarized using mean and standard error or median
and interquartile range as appropriate and analyzed using
either a t-test or a Wilcoxon rank-sum test. Predictors of
time to C-IRIS were analyzed using univariable and
multivariable Cox proportional-hazards regression. The
number of C-IRIS events limited multivariable modeling
to three concurrent predictors in any one model. Hazard
proportionality was assessed through the analysis of scaled
Schoenfeld residuals.
Predictors of culture negativity in the clearance CSF
sample were analyzed using logistic regression. Goodness-
of-fit of logistic models was assessed using a Hosmer and
Lemeshow test. Clinical outcomes of CSF culture
negativity were determined by survival analysis. All
reported P-values are two-tailed and in all analyses
P< 0.05 was considered significant. All analyses were
performed using Stata v.12 (StataCorp, College Station,
Texas, USA) and GraphPad Prism v5 (La Jolla, California,
USA). The funding source took no part in the design or
analysis of the study.Results
Patient recruitment and demographics
One hundred and thirty patientswere enrolled (Fig. 1); one
was erroneously enrolled (HIV-seronegative) and another
commenced and ceased cARToutside of protocol. Of the
remaining 128 patients, three were lost to follow-up
(declined to return for cART) and 19 (14.8%) died during
induction antifungal therapy before initiating cART. One
hundred and six patients started cARTat a median time of
18 days (interquartile range 15–22) after cryptococcal
meningitis diagnosis. Post-cART follow-up accrued to
1803 patient-weeks. The median age was 33.5 years;
median CD4þ T-cell count was 35 cells/ml and HIV
plasma viral load was 5.2 log10 copies/ml. All patients were
positive for CSF CrAg and 118 (92.2%) had CSF culture-
confirmed cryptococcal infection.
Neurological deterioration and survival
Forty-three patients had neurological deterioration
events (n¼ 27, 25.5% C-IRIS; and n¼ 16, 15.1%horized reproduction of this article is prohibited.
Co
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Fig. 1. Patient recruitment and disposition flowchart. cART, combination antiretroviral therapy; C-IRIS, cryptococcosis-
associated immune reconstitution inflammatory syndrome; ND, neurological deterioration.neurological deterioration-not C-IRIS), whereas 63 had
no neurological deterioration (59.4%; Fig. 1). Eight
patients experienced multiple neurological deterioration
events. Clinical features of neurological deterioration
included headache, nausea/vomiting, neck pain, and
confusion, which occurred in 74.6, 58.2, 38.2, and
21.8%, respectively. The neurological deterioration
events (n¼ 55) were classified as C-IRIS (n¼ 34;
61.8%), neurological deterioration-not C-IRIS (n¼ 14;
25.5%), and indeterminate (n¼ 7; 12.7%). The causes of
neurological deterioration-not C-IRIS were cryptococ-
cal persistence/relapse (n¼ 6), shunt-related problems
(n¼ 2), renal failure (n¼ 2), pulmonary TB (n¼ 2),
varicella-zoster infection (n¼ 1), and migraine (n¼ 1).
Of the seven indeterminate events, three died in hospital
without sufficient investigations and four died out of
hospital. Twenty-one (19.8%) deaths were recorded after
cART commencement. Survival at 6 months post-cART
was 80.2% in the cohort who commenced cART.
Predictors of cryptococcosis-associated immune
reconstitution inflammatory syndrome
The C-IRIS group, when compared with the no
neurological deterioration group, had lower CD4þ
T-cell counts pre-cART (median 16 vs. 36 cells/ml,
P¼ 0.015), but there was no significant difference in age,
sex, HIV viral load, or BMI between groups (Table 1).
Seizures at cryptococcal meningitis presentation were
more common in the C-IRIS group (P¼ 0.028).pyright © Lippincott Williams & Wilkins. UnauthoOn the basis of the first CSF sample collected at
cryptococcal meningitis diagnosis, the C-IRIS group
compared to the no neurological deterioration group,
had a lower CSF protein level (median 0.70 vs. 0.91 g/l,
P¼ 0.013); lower CSF neutrophil count (median 0 vs.
6 cells/ml, P¼ 0.018); lower CSF lymphocyte count
(median 10 vs. 34 cells/ml, P¼ 0.006); and higher CSF
cryptococcal burden as measured by QnCC (median
111 000 vs. 1800 colony forming unit (CFU)/ml,
P¼ 0.004; Table 1).
When we assessed the clearance lumbar puncture
(median time 15 days from cryptococcal meningitis
diagnosis), fewer patients in the C-IRIS group compared
to the no neurological deterioration group were culture
negative (25.9 vs. 61.9%, P¼ 0.002); and the C-IRIS
group had lower CSF protein levels and total leucocyte
counts (median 0.57 vs. 0.94 g/l, P¼ 0.003 and 18 vs. 39,
P¼ 0.045, respectively; Table 1). QnCCs for clearance
lumbar puncture were available for 97.2% of patients and
were not significantly different between groups. Lumbar
puncture opening pressure, CSF glucose, and CSF and
serum CrAg were not significantly different between
groups.
CD4þT-cell counts remained lower in the C-IRIS group
compared to the no neurological deterioration group at
week 04 (P¼ 0.0042) but were similar by week 12,
whereas there were no differences in HIV viral loadrized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 2. Three-parameter multivariate analysis for cryptococcosis-
associated immune reconstitution inflammatory syndrome.
Parameter P HR 95% CI
Clearance LP – culture negative 0.010 0.2691 0.0986–0.7342
CD4þ T cell over 24 weeks 0.026 0.9895 0.9804–0.9987
Clearance LP – CSF protein 0.059 0.5282 0.2726–1.0233
CI, confidence interval; CSF, cerebrospinal fluid; HR, hazard ratio; LP,
lumbar puncture.(supplementary Figure 1, http://links.lww.com/QAD/
A364). Analyzing time-varying CD4þ T-cell counts over
24 weeks demonstrated that every 100 CD4þ T-cell
increase on cARTwas associated with a 62% reduction in
the rate of C-IRIS [hazard ratio (HR) 0.28, 95%
confidence interval (CI) 0.13–0.59, P¼ 0.001]. Changes
in serum CrAg level over 24 weeks were not associated
with C-IRIS (P¼ 0.324).
Using multivariable analysis, a negative CSF cryptococcal
culture at cART initiation and increasing CD4þ T cells
over 24 weeks of cART were both independently
associated with decreased rates of C-IRIS (P¼ 0.010,
HR 0.27 and P¼ 0.026, HR 0.99, respectively), whereas
lower CSF protein on the clearance lumbar puncture
showed a trend toward an association with decreased rates
of C-IRIS (P¼ 0.059, HR 0.53) (Table 2).
Predictors of cerebrospinal fluid cryptococcal
culture negativity and its clinical outcomes
On the basis of the clearance lumbar puncture results
available for all 106 patients, patients were divided into
‘culture-negative’ (n¼ 51, 48.1%) or ‘culture-positive’
(n¼ 55, 51.9%) groups. The number of amphotericin
doses (median 14 in both groups) and duration of
antifungal therapy prior to the clearance lumbar puncture
(14 vs. 15 days) and time to starting cART following
cryptococcal meningitis diagnosis (17 vs. 20 days) were
similar between groups (P¼ 0.332, 0.255, and 0.180,
respectively) (Table 3).
The culture-negative compared to the culture-positive
group had higher pre-cART CD4þ T-cell counts
(median 42 vs. 33 cells/ml, P¼ 0.009), higher neutrophil
counts in CSF at cryptococcal meningitis presentation
(median 6 vs. 0 cells/ml, P¼ 0.031); and higher
lymphocyte and total leucocyte counts in CSF from
the clearance lumbar puncture (median 34 vs. 16 cells/ml,
P¼ 0.006 and 54 vs. 28 cells/ml, P¼ 0.012, respectively)
(Table 3). Seizures as a presenting feature were less
common in the culture-negative group (3.6 vs. 20.0%,
P¼ 0.023). CSF QnCC performed on the first available
CSF and the clearance lumbar puncture were both lower
in the culture-negative compared to the culture-positive
group (P¼<0.001 and 0.006, respectively) as were the
CSF and serum CrAg titers (P¼ 0.015 and 0.002,
respectively) (Table 3).pyright © Lippincott Williams & Wilkins. UnauthoUsing multivariable analysis, lower QnCC in CSF from
the clearance lumbar puncture and serum CrAg were
independent predictors of CSF culture negativity
(P¼ 0.007, odds ratio 0.063, 95% CI 0.008–0.468 and
P¼ 0.025, odds ratio 0.998, 95% CI 0.996–1.000,
respectively). CSF lymphocyte count and blood CD4þ
T-cell count contributed to the model (P¼ 0.408 and
0.610, respectively) (Table 3).
To test the hypothesis that CSF cryptococcal clearance
prior to cART commencement is associated with
improved clinical outcomes, we specifically compared
neurological deterioration, C-IRIS, cryptococcal
relapse/persistence and death between these two groups.
Using survival analysis, the culture-negative group
compared to the culture-positive group had significantly
reduced rates of neurological deterioration (23.5 vs.
56.4%, HR 0.33, 95% CI 0.18–0.60, P¼ 0.0003) and C-
IRIS (13.7 vs. 36.4%, HR 0.33, 95% CI 0.15–0.70,
P¼ 0.0042). All neurological deterioration caused by
cryptococcal relapse/persistence (n¼ 11) occurred in the
culture-positive group (HR 0.12, 95% CI 0.04–0.38,
P¼ 0.0004) (Fig. 2). There were fewer deaths in the
culture-negative group but the difference was not
statistically significant (13.7 vs. 25.5%, HR 0.52, 95%
CI 0.22–1.22, P¼ 0.13) (Fig. 2).Discussion
Persistent CSF cryptococcal growth at initiation of cART
and advanced immunodeficiency are independent pre-
dictors of C-IRIS. Importantly, patients who cleared
cryptococcus from their CSF prior to commencing
cART not only experienced significantly lower rates of
C-IRIS, but also had fewer episodes of neurological
deterioration and cryptococcal relapse/persistence,
suggesting that cryptococcal clearance prior to initiation
of cART is a significant determinant of clinical outcome
in HIV-infected patients with cryptococcal meningitis, as
supported by a recent review [16]. Previous studies show
slower rates of cryptococcal clearance are associated with
increased early mortality [17].
We demonstrated that a lower blood CD4þ T-cell count,
CSF protein, lymphocyte and neutrophil count, and, in
particular, a higher cryptococcal burden are associated
with an increased risk of developing C-IRIS. These
findings confirm previously identified predictors of
C-IRIS including a lower baseline CD4þ T-cell count
[18,19] and reduced CSF inflammation [20]. Others have
shown that a higher CSF CrAg and lower CSF white cell
count to be associated with worsened cryptococcal
meningitis outcomes [21]. We show gains in CD4þT-cell
count as protective for C-IRIS highlighting immune
competence as beneficial. This suggests the immuno-
pathology underlying C-IRIS may not reflect therized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hazard ratio  0.3288 (95% CI 0.1791 to 0.6036); P = 0.0003

























C negative 45 (88.1%) 42 (82.1%) 38 (76.1%)n = 51
C positive 40 (73.6%) 27 (52.0%) 21 (40.0%)n = 55
C negative 48 (100%) 48 (100%) 44 (100%)n = 51
C positive 47 (92.4%) 27 (85.4%) 32 (75.9%)n = 55
C negative 48 (92.2%) 48 (92.2%) 44 (86.3%)n = 51
C positive 51 (90.9%) 42 (74.5%) 41 (74.5%)n = 55
C negative 46 (93.8%) 43 (89.7%) 40 (85.4%)n = 51
C positive 40 (80.6%) 30 (74.6%) 27 (59.3%)n = 55
Neurological deterioration







Hazard ratio  0.3292 (95% CI 0.1539 to 0.7045); P = 0.0042





















Hazard ratio 0.1163 (95% CI 0.0354 to 0.3818); P = 0.0004



































Hazard ratio 0.5160 (95% CI 0.2190 to 1.2160); P = 0.1302
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   Culture negative
Culture positive
Deaths
Fig. 2. Kaplan–Meier curves on the impact of cerebrospinal fluid (CSF) cryptococcal culture negativity pre-combination
antiretroviral therapy (cART) on neurological deterioration (ND), cryptococcosis-associated immune reconstitution inflam-
matory syndrome (C-IRIS), cryptococcal relapse/persistence and mortality. Solid line (culture negative) and broken line (culture
positive). Patients who were able to achieve CSF cryptococcal culture negativity prior to cART commencement had significantly
lower episodes of ND, C-IRIS, and cryptococcal relapse/persistence compared to those who remained cryptococcal culture
positive. Survival was improved in the culture-negative group but this was not statistically significant. CI, confidence interval; HR,
hazard ratio.numerical gain of CD4þ T cells but rather the restoration
of a dysfunctional immune response.
Further, to our knowledge, we demonstrate for the first
time that a persistent high cryptococcal burden in the
CSF prior to initiation of cART is also a risk factor for
C-IRIS. Despite a higher fungal burden, the more
immunodeficient C-IRIS group seemed less able to
mount an adequate cellular response, possibly explained
by the immunosuppressive effects of the polysaccharide
capsule [22]. Early reports of cryptococcal meningitis
demonstrated an acellular CSF profile to be associated
with early death and treatment failure [23]; we show this
is also associated with an increased risk for C-IRIS.
Our finding that a gain in CD4þ T cells is protective for
C-IRIS may seem counterintuitive and is in contrast to a
previous study in C-IRIS often quoted as evidence for a
rapid rise in CD4þ T cells as a risk factor for IRIS [24].
However, this study reported the absolute difference in
CD4þ T cells from baseline to 6 months and four of the
11 patients in their C-IRIS group died within 6 months;
hence, the small remaining number of patients may havepyright © Lippincott Williams & Wilkins. Unauthoskewed the findings of the study. In contrast, our study
measured CD4þ T-cell counts repeatedly at weeks 4, 12,
and 24 in a much larger number of patients and used a
time-to-event analysis. We have demonstrated in this
cohort of patients that C-IRIS is not associated with
an increase in circulating CD4þ T cells reactive with
cryptococcal mannoprotein [25]. Although, compart-
mentalization of T-cell responses to the CNS is possible, a
role for innate immune responses should be considered, as
suggested in TB-IRIS [26,27].
CSF protein is usually elevated in patients with
cryptococcal meningitis and lower levels have been
associated with higher cryptococcal meningitis early
mortality [28]. Patients with C-IRIS had a significantly
lower CSF protein at cryptococcal meningitis presen-
tation than the no neurological deterioration group, as
previously reported [20], and this difference was further
exaggerated during induction antifungal therapy. An
explanation for this is not immediately apparent. CSF
proteins are derived from passage of proteins across the
blood–brain barrier; from inflammatory cells [22],
damage to and necrosis of the meninges and neuronalrized reproduction of this article is prohibited.
Cryptococcosis-IRIS predictors Chang et al. 2097cells [22] and from cryptococcal cell wall breakdown.
Exploratory proteomic analysis may be instructive as more
than 2630 proteins have been found in normal CSF [29].
Early cryptococcal clearance has been used in treatment
studies as a measure of mycological success [30–32] but to
date, this has not been accepted as a surrogate marker of
clinical success. We clearly show that achieving a negative
CSF culture prior to starting cART conferred significantly
improved clinical outcomes. The relatively low number of
deaths in our study group may not have conferred adequate
power to demonstrate a statistically significant difference in
mortality during the defined follow-up period. Crypto-
coccal meningitis management guidelines [14,33,34] in
HIV-infected patients offer a rank order of recommended
antifungal agents with varying durations, based predomi-
nantlyon fungal clearance efficacy. Studies have shown that
early mortality in cryptococcal meningitis correlates
strongly with the baseline CSF QnCC [31]. We show
that in patients receiving similar doses of amphotericin,
those with a higher CD4þ T-cell count, lower QnCC,
lower CSF and serum CrAg, and a more cellular CSF are
more likely to achieve CSF culture negativity. We propose
that patients could be potentially stratified by fungal burden
at cryptococcal meningitis diagnosis, degree of immuno-
deficiency and CSF profile into two-tier or three-tier risk
strata with the goal of achieving CSF culture negativity,
prior to cART commencement. Those with poor
predictive markers could be targeted for enhanced
antifungal therapy or adjunctive therapy including inter-
feron-g therapy [35].
No patients in the culture-negative group developed
cryptococcal persistence/relapse, suggesting that empirical
re-induction therapy in this group is not always necessary.
QnCCs, although more labor-intensive, may serve as a
baseline measure of fungal burden to be compared to future
neurological deterioration events; an increase in QnCC
compared to baseline may suggest cryptococcal relapse
necessitating intensification of antifungal therapy.
Timing of cART initiation in the presence of concurrent
opportunistic infections is contentious. In cryptococcal
meningitis-HIV co-infection, one small randomized
controlled study (RCT) showed excess mortality in
the early arm compared to the delayed arm (72-h vs.
10 weeks after cryptococcal meningitis diagnosis) [10],
whereas a smaller RCT demonstrated higher C-IRIS in
the early arm vs. the delayed arm (within 7–10 days vs.
after 28 days of antifungal therapy commencement) [8].
Fluconazole was used as induction therapy in the former
study and limited therapeutic lumbar punctures were
performed [10], two important factors that differed from
our study. In the latter study, 0.7 mg/kg of amphotericin
was used [8] and the authors previously reported the
benefits of inpatient cART commencement in reducing
patient mortality in HIV-cryptococcal meningitis-TB
coinfected men [36]. The large ‘cryptococcal meningitisCopyright © Lippincott Williams & Wilkins. Unautoptimal ART timing’ study was terminated at 177 persons
(35% of target enrolment), for reasons of unacceptable
mortality in the early arm compared to the deferred arm
(day 9–13 vs. 5 weeks after cryptococcal meningitis
diagnosis) [9]. Patients with low CSF white blood cell
counts and altered mental state, in particular, did better in
the deferred arm [9]. We speculate patients in early arms
of these three studies may have had larger residual fungal
burden at cART initiation. Adjunctive management
strategies such as intracranial pressure management may
not have been optimally addressed.
Other prospective non-randomized cryptococcal menin-
gitis studies commenced cART at a median of 5 weeks
(range 1–8) [37] to as late as after 7 weeks [38] after
cryptococcal meningitis diagnosis. We commenced cART
at a median time of 18 days after cryptococcal meningitis
diagnosis and achieved a remarkable overall survival of 80%
at 24 weeks post-cART initiation (higher than either of the
cryptococcal meningitis optimal ART timing study arms).
Delaying cART to conform to current RCT findings in
resource-limited settings may risk further comorbidities,
hospital-acquired infections, unmonitored deterioration,
losses to follow-up and death as illustrated by a 29% loss
between completion of induction therapy and cART
initiation in a Ugandan study [28].
We acknowledge that our study has limitations. Until a
firm diagnostic marker for C-IRIS is developed, studies
of C-IRIS are open to criticism. Our experienced end-
point review committee actively excluded indeterminate
neurological deterioration events and the 100% follow-
up rate enhanced the validity of our comparator no
neurological deterioration group. We focused solely on
the central nervous system manifestations and may have
underestimated the true incidence of C-IRIS. We had
limited histopathological confirmation.
In summary, persistent cryptococcal burden and advanced
immunodeficiency prior to commencing cART may
drive aberrant immune responses against Cryptococci
leading to C-IRIS. Our study demonstrated that CSF
cryptococcal clearance prior to initiation of cART is
associated with improved clinical outcomes. Where
assessing this is not possible, a combination of markers
(lower CD4þ T-cell count, higher CSF and serum CrAg,
and lower CSF neutrophil and lymphocyte counts pre-
cART) might be used to predict a higher cryptococcal
burden. The benefits of attaining CSF cryptococcal
culture negativity prior to cART commencement should
be further evaluated in future clinical studies.Acknowledgements
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